These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 17243195

  • 21. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH, Schmitt FA, Olin JT, Memantine MEM-MD-02 Study Group.
    Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
    [Abstract] [Full Text] [Related]

  • 22. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis.
    Livingston G, Katona C.
    Int J Geriatr Psychiatry; 2004 Oct; 19(10):919-25. PubMed ID: 15449303
    [Abstract] [Full Text] [Related]

  • 23. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.
    Neurology; 2007 Jul 31; 69(5):459-69. PubMed ID: 17664405
    [Abstract] [Full Text] [Related]

  • 24. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.
    Görtelmeyer R, Erbler H.
    Arzneimittelforschung; 1992 Jul 31; 42(7):904-13. PubMed ID: 1418054
    [Abstract] [Full Text] [Related]

  • 25. Memantine in everyday clinical practice: a comparison of studies in Germany and Greece.
    Förstl H, Stamouli SS, Janetzky W, Galanopoulos A, Karageorgiou C, Tzanakaki M.
    Dement Geriatr Cogn Disord; 2011 Jul 31; 32(4):267-72. PubMed ID: 22237255
    [Abstract] [Full Text] [Related]

  • 26. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan 31; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 27. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.
    Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, Jarvik JG, Miller EN, Singer EJ, Ellis RJ, Kolson DL, Simpson D, Nath A, Berger J, Shriver SL, Millar LL, Colquhoun D, Lenkinski R, Gonzalez RG, Lipton SA, Adult AIDS Clinical Trial Group (ACTG) 301, 700 Teams, HIV MRS Consortium.
    AIDS; 2007 Sep 12; 21(14):1877-86. PubMed ID: 17721095
    [Abstract] [Full Text] [Related]

  • 28. Memantine enhances autonomy in moderate to severe Alzheimer's disease.
    Rive B, Vercelletto M, Damier FD, Cochran J, François C.
    Int J Geriatr Psychiatry; 2004 May 12; 19(5):458-64. PubMed ID: 15156547
    [Abstract] [Full Text] [Related]

  • 29. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B, Grossberg G, Frölich L, Farlow M, Zechner S, Nagel J, Lane R.
    Neurology; 2007 Jul 24; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [Abstract] [Full Text] [Related]

  • 30. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
    Antonanzas F, Rive B, Badenas JM, Gomez-Lus S, Guilhaume C.
    Eur J Health Econ; 2006 Jun 24; 7(2):137-44. PubMed ID: 16670912
    [Abstract] [Full Text] [Related]

  • 31. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
    Choi SH, Park KW, Na DL, Han HJ, Kim EJ, Shim YS, Lee JH, Expect Study Group.
    Curr Med Res Opin; 2011 Jul 24; 27(7):1375-83. PubMed ID: 21561398
    [Abstract] [Full Text] [Related]

  • 32. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
    Grossberg GT, Manes F, Allegri RF, Gutiérrez-Robledo LM, Gloger S, Xie L, Jia XD, Pejović V, Miller ML, Perhach JL, Graham SM.
    CNS Drugs; 2013 Jun 24; 27(6):469-78. PubMed ID: 23733403
    [Abstract] [Full Text] [Related]

  • 33. An open-label, flexible-dose study of memantine in major depressive disorder.
    Ferguson JM, Shingleton RN.
    Clin Neuropharmacol; 2007 Jun 24; 30(3):136-44. PubMed ID: 17545748
    [Abstract] [Full Text] [Related]

  • 34. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.
    van Dyck CH, Tariot PN, Meyers B, Malca Resnick E, Memantine MEM-MD-01 Study Group.
    Alzheimer Dis Assoc Disord; 2007 Jun 24; 21(2):136-43. PubMed ID: 17545739
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial.
    Ditzler K.
    Arzneimittelforschung; 1991 Aug 24; 41(8):773-80. PubMed ID: 1781796
    [Abstract] [Full Text] [Related]

  • 36. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R.
    Clin Ther; 2007 Apr 24; 29(4):563-80. PubMed ID: 17617280
    [Abstract] [Full Text] [Related]

  • 37. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT.
    Pharmacotherapy; 2007 Mar 24; 27(3):399-411. PubMed ID: 17316151
    [Abstract] [Full Text] [Related]

  • 38. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
    Grossberg GT, Pejović V, Miller ML, Graham SM.
    Dement Geriatr Cogn Disord; 2009 Mar 24; 27(2):164-72. PubMed ID: 19194105
    [Abstract] [Full Text] [Related]

  • 39. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
    Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Takase T, Ohbayashi T.
    Dement Geriatr Cogn Disord; 2009 Mar 24; 27(3):232-9. PubMed ID: 19246907
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.